{"i": ["H5N1 vaccines", "live - attenuated avian influenza H9N2 and H7N3 vaccines", "Ad4 vector vaccines", "placebo .", "H5N1 or H5N2", "Ad4 - H5 - Vtn vector", "replicating adenovirus serotype 4 vector vaccine", "inactivated H5N1 subvirion vaccine", "vaccinia", "Vaccine or placebo", "H5N1 boost", "Ad4 - H5", "inactivated parenteral subvirion H5N1 vaccine", "Replication - competent virus vector vaccines", "Ad4 - H5 - Vtn vaccine or placebo", "placebo", "Ad4 - H5 - Vtn vaccine", "Ad4 - H5 - Vtn or placebo .", "inactivated H5N1", "Ad4 - H5 - Vtn", "vaccine or placebo", "oral Ad4 replicating vector approach", "placebo - controlled", "inactivated H5N1 vaccine", "oral adenovirus serotype 4 vector vaccine candidate ( Ad4 - H5 - Vtn )", "interferon \u03b3", "Ad4 - H5 - Vtn vector vaccine", "live - attenuated seasonal influenza vaccine", "inactivated parenteral H5N1 vaccine .", "inactivated subvirion H5N1", "Ad4 - H5 - Vtn or placebo", "Ad4 and Ad7 vaccines"], "o": ["microneutralisation seroconversion", "Ad4 - H5 - Vtn virus", "haemagglutinin - specific cellular immune responses", "antibody response rates", "Severe tenderness", "cellular immune response and vaccine take", "antibody responses", "HAI responses", "IgG responses in nasal mucosal samples", "Interleukin - 2 responses", "Seroprotection", "Safety", "toxic effects", "safety and immunogenicity", "occurrence of tenderness at the injection site", "seroconversion by haemagglutination - inhibition ( HAI ),", "Median response for interleukin 2", "vaccine take , pre - boost cellular immune response , and post - boost HAI and microneutralisation antibody response", "Post - boost HAI GMT", "seroprotection", "- related adverse events", "post - boost seroprotection and seroconversion", "- boost antibody responses", "HAI geometric mean titre ( GMT ).", "cumulative frequency of abdominal pain , diarrhoea , and nasal congestion", "HAI and neutralising antibody responses", "occurrence of HAI seroconversion", "Ad4 seroconversion and GMTs", "pancreatitis", "Headache", "seroconversion and GMTs", "seroconversion by HAI", "PCR - positive swabs", "IgG ELISA response", "HAI GMT", "symptoms of reactogenicity", "haemagglutinin - specific antibody responses", "virus in throat swabs , rectal swabs , and blood samples", "Serum haemagglutination - inhibition ( HAI ), 17 microneutralisation18", "Continuous HAI , microneutralisation , and Ad4 neutralisation", "GMT", "HAI geometric mean titre ( GMT", "After - boost responses", "antibody response", ", rectal , and nasal mucosal samples", "Median response", "seroprotective titres", "systemic reactogenicity", "vaccine virus or so - called vaccine take", "PCR - positive rectal swabs", "asymptomatic seroconversions", "reactogenicity", "occurrence of IgG and IgA response", "recurrence of vaccine virus replication", "HAI antibody responses", "neutralising antibody response to", "injection site pain", "Replication of the Ad4", "occurrence of seroconversion", "asymptomatic seroconversion to Ad4", "occurrence of take", "heterologous ( cross - clade ) HAI response", "HAI seroconversion", "HAI and microneutralisation response", "Recurrence ( second take ) of Ad4 - H5 - Vtn replication", "Adverse events", "norovirus - associated gastroenteritis", "Plasma IgA ELISA seroresponse", "IgG seropositive", "Occurrence of Ad4 seroconversion", "protective HAI titre", "Ad4 immunity", "Local reactogenicity", "adverse events", "Shedding of the Ad4 - H5 - Vtn", "Interferon - \u03b3 T - cell response to recombinant H5 haemagglutinin protein or peptide pools", "cumulative take", "serious adverse events : hallucinations"]}